verapamil has been researched along with Cerebrovascular Disorders in 27 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(S)-Emopamil has a less potent calcium antagonistic effect (EC50 = 270 nmol/l) on the aorta than verapamil and gallopamil (EC50 = 35 and 14 nmol/l, respectively)." | 5.28 | (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile. ( Hofmann, HP; Raschack, M; Unger, L, 1989) |
| "A 20-year-old female with hemiplegic migraine was treated during an acute attack with intravenous verapamil, which reproducibly resolved the headache within 20 min but did not affect her hemiplegia." | 3.74 | Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil. ( Dulli, DA; Hsu, DA; Kiff, JE; Rowley, HA; Stafstrom, CE, 2008) |
| "In stroke-prone spontaneously hypertensive rats, oral long-term treatment with verapamil, propranolol, hydrochlorothiazide, and dihydralazine attenuated the development of hypertension." | 3.67 | Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. ( Gries, J; Kretzschmar, R; Neumann, BW, 1989) |
| " However, 4-hourly dosing is a practical limitation and verapamil has been proposed as an alternative." | 3.01 | Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review. ( Bacchi, S; Bagster, M; Collins, L; Goh, R; Gupta, A; Kleinig, O; Kleinig, T; Kovoor, J; Lam, L; Proudman, W; Schultz, D; Zhang, R, 2023) |
| " These differences can be attributed at least in part to the low catecholamine profile of verapamil and the marked rapid adrenergic activation with short-acting nifedipine, which could also explain the adverse effects found when this agent is given to patients with acute coronary syndromes." | 2.40 | Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. ( Opie, LH, 1997) |
| "(S)-Emopamil has a less potent calcium antagonistic effect (EC50 = 270 nmol/l) on the aorta than verapamil and gallopamil (EC50 = 35 and 14 nmol/l, respectively)." | 1.28 | (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile. ( Hofmann, HP; Raschack, M; Unger, L, 1989) |
| "Diltiazem-treated animals had decreased cerebral H2O content, but had a marked increase in the area of nonperfused brain, a finding associated with the high incidence of transtentorial herniation in the diltiazem-treated animals." | 1.27 | Effects of verapamil and diltiazem on acute stroke in cats. ( Dempsey, RJ; Donaldson, DL; Meyer, KL; Roy, MW; Tibbs, PA; Young, AB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (29.63) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, L | 1 |
| Lam, L | 1 |
| Kleinig, O | 1 |
| Proudman, W | 1 |
| Zhang, R | 1 |
| Bagster, M | 1 |
| Kovoor, J | 1 |
| Gupta, A | 1 |
| Goh, R | 1 |
| Bacchi, S | 1 |
| Schultz, D | 1 |
| Kleinig, T | 1 |
| Ospel, JM | 1 |
| Wright, CH | 1 |
| Jung, R | 1 |
| Vidal, LLM | 1 |
| Manjila, S | 1 |
| Singh, G | 1 |
| Heck, DV | 1 |
| Ray, A | 1 |
| Blackham, KA | 1 |
| Fletcher, JJ | 1 |
| Kramer, AH | 1 |
| Bleck, TP | 1 |
| Solenski, NJ | 1 |
| Chatterjee, N | 1 |
| Domoto-Reilly, K | 1 |
| Fecci, PE | 1 |
| Schwamm, LH | 1 |
| Singhal, AB | 1 |
| French, KF | 1 |
| Hoesch, RE | 1 |
| Allred, J | 1 |
| Wilder, M | 1 |
| Smith, AG | 1 |
| Digre, KB | 1 |
| La Barge, DV | 1 |
| Ducros, A | 1 |
| Hsu, DA | 1 |
| Stafstrom, CE | 1 |
| Rowley, HA | 1 |
| Kiff, JE | 1 |
| Dulli, DA | 1 |
| Hansen, JF | 1 |
| Novosel, D | 1 |
| Lang, MG | 1 |
| Noll, G | 1 |
| Lüscher, TF | 1 |
| Salerno, SM | 1 |
| Zugibe, FT | 1 |
| Blackshear, JL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Safford, RE | 1 |
| Hammill, SC | 1 |
| Münter, K | 1 |
| Hergenröder, S | 1 |
| Jochims, K | 1 |
| Kirchengast, M | 1 |
| Hunter, AJ | 1 |
| Opie, LH | 1 |
| Black, HR | 1 |
| Elliott, WJ | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Grimm, RH | 1 |
| Hansson, L | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Sleight, P | 1 |
| Weber, MA | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Wittes, J | 1 |
| Zanchetti, A | 1 |
| Fakouhi, TD | 1 |
| Shah, AR | 1 |
| Passalacqua, BR | 1 |
| Smeda, JS | 1 |
| Burtsev, EM | 3 |
| Shprakh, VV | 1 |
| Savkov, VS | 3 |
| Ishchenko, MM | 1 |
| Dorogiĭ, AN | 1 |
| Nechaĭ, EE | 1 |
| Shkrobot, SI | 1 |
| Gries, J | 1 |
| Kretzschmar, R | 1 |
| Neumann, BW | 1 |
| Hofmann, HP | 1 |
| Raschack, M | 1 |
| Unger, L | 1 |
| Zhuravlev, AK | 1 |
| Murashko, VV | 1 |
| Kamchatnov, PR | 1 |
| Stern, WE | 1 |
| Hakim, AM | 1 |
| Roy, MW | 1 |
| Dempsey, RJ | 1 |
| Meyer, KL | 1 |
| Donaldson, DL | 1 |
| Tibbs, PA | 1 |
| Young, AB | 1 |
5 reviews available for verapamil and Cerebrovascular Disorders
| Article | Year |
|---|---|
Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review.
Topics: Cerebrovascular Disorders; Humans; Nimodipine; Vasoconstriction; Vasospasm, Intracranial; Verapamil | 2023 |
[Acute and chronic headaches].
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri | 1996 |
Calcium antagonists: their role in neuroprotection.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Calcium Channels; Cerebrovascular Disorders; Dihy | 1997 |
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Topics: Calcium Channel Blockers; Catecholamines; Cerebrovascular Disorders; Drug Evaluation; Gastrointestin | 1997 |
2 trials available for verapamil and Cerebrovascular Disorders
| Article | Year |
|---|---|
Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension.
Topics: Cerebrovascular Disorders; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Follow-Up Studies; | 1993 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
20 other studies available for verapamil and Cerebrovascular Disorders
| Article | Year |
|---|---|
Intra-Arterial Verapamil Treatment in Oral Therapy-Refractory Reversible Cerebral Vasoconstriction Syndrome.
Topics: Adult; Aged; Cerebrovascular Disorders; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2020 |
Overlapping features of eclampsia and postpartum angiopathy.
Topics: Adult; Cerebrovascular Disorders; Eclampsia; Female; Headache; Humans; Methylprednisolone; Nicardipi | 2009 |
Licorice-associated reversible cerebral vasoconstriction with PRES.
Topics: Administration, Oral; Brain; Cerebral Angiography; Cerebrovascular Circulation; Cerebrovascular Diso | 2010 |
Repetitive use of intra-arterial verapamil in the treatment of reversible cerebral vasoconstriction syndrome.
Topics: Adult; Aged, 80 and over; Cerebral Arteries; Cerebrovascular Disorders; Female; Humans; Radiography; | 2012 |
Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil.
Topics: Adult; Brain; Cerebral Angiography; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular | 2008 |
Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Cerebrovascula | 1994 |
Calcium channel antagonists. What do the second-generation agents have to offer?
Topics: Arteriosclerosis; Calcium Channel Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Dihy | 1994 |
Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium | 1996 |
Case report: sustained-release verapamil overdose causing stroke: an unusual complication.
Topics: Cerebrovascular Disorders; Delayed-Action Preparations; Drug Overdose; Female; Humans; Middle Aged; | 1992 |
Cerebral vascular changes associated with hemorrhagic stroke in hypertension.
Topics: Aging; Animals; Cerebral Arteries; Cerebral Hemorrhage; Cerebrovascular Circulation; Cerebrovascular | 1992 |
[A differential approach to cavinton and finoptin treatment of patients with circulatory encephalopathies].
Topics: Aged; Cerebrovascular Circulation; Cerebrovascular Disorders; Humans; Middle Aged; Phosphodiesterase | 1992 |
[Vasoactive and cardiotonic drugs in the treatment of initial manifestations of cerebrovascular insufficiency in occlusive diseases of major blood vessels of the head].
Topics: Adult; Aged; Aminophylline; Arterial Occlusive Diseases; Carotid Artery Diseases; Cerebrovascular Di | 1991 |
Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Dihydralazine; Heart; H | 1989 |
[Calcium antagonists (finoptin and senzit) in the treatment of cerebrovascular disorders].
Topics: Adult; Age Factors; Arteriosclerosis; Cerebrovascular Disorders; Drug Evaluation; Fendiline; Humans; | 1989 |
[Experience in the use of finoptin (verapamil) in cerebrovascular diseases].
Topics: Cerebrovascular Disorders; Electrocardiography; Hemodynamics; Humans; Middle Aged; Plethysmography, | 1989 |
(S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
Topics: Animals; Binding, Competitive; Calcium Channel Blockers; Cerebrovascular Disorders; Female; Guinea P | 1989 |
[Effect of corinfar and finoptin on lipid peroxidation].
Topics: Adult; Calcium Channel Blockers; Cerebrovascular Disorders; Humans; Lipid Peroxides; Middle Aged; My | 1988 |
Effects of verapamil and diltiazem: correction.
Topics: Animals; Benzazepines; Cats; Cerebrovascular Disorders; Diltiazem; Verapamil | 1986 |
Cerebral acidosis in focal ischemia: II. Nimodipine and verapamil normalize cerebral pH following middle cerebral artery occlusion in the rat.
Topics: Acidosis; Animals; Arterial Occlusive Diseases; Brain; Brain Diseases; Brain Ischemia; Calcium Chann | 1986 |
Effects of verapamil and diltiazem on acute stroke in cats.
Topics: Animals; Benzazepines; Blood Volume; Brain; Brain Edema; Cats; Cerebrovascular Circulation; Cerebrov | 1985 |